Mimi-Q offers an innovative platform that accelerates drug development by predicting clinical trial outcomes through virtual patient modeling and adaptive in vitro testing. Their proprietary software generates data on drug behavior in diverse human populations using a patented wet lab disease response model. This integrated simulation technology significantly reduces development timelines and improves success rates for pharmaceutical research.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug testing methods often fail to accurately replicate the complex pharmacokinetics observed in diverse human populations, leading to inaccurate predictions of drug behavior and clinical outcomes. This can result in costly late-stage failures and delays in bringing crucial medications to market.
Solution
Mimi-Q offers a virtual clinical trial platform that leverages patient modeling and adaptive in vitro testing to predict drug behavior and clinical outcomes. The platform uses proprietary software to simulate drug behavior in diverse patient populations, incorporating various patient characteristics. Paired with a patented wet lab disease response model that generates data on drug response, Mimi-Q's virtual clinical trial simulator bundles data from diverse sources to predict results for various clinical scenarios. This approach aims to streamline the drug development process, reduce development costs, and accelerate access to medications.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions seeking to accelerate drug development, reduce costs, and improve the accuracy of clinical trial predictions.
Features
- Virtual Patient Generator: Software that simulates drug behavior in human populations, accounting for diverse patient characteristics.
- Wet Lab Disease Response Model: Patented technology that generates data on drug response after administration.
- Virtual Clinical Trial Simulator: Platform that integrates data from diverse sources to predict clinical trial outcomes for various scenarios.